SkyePharma CEO Axel Mueller has resigned “to pursue other interests,” according to the company, and will be replaced by current Chief Financial Officer Peter Grant. The company’s announcement says that Grant, who has been CFO since 2006, “will retain responsibility for the Group’s financial matters and will oversee the continuing activities to achieve Flutiform regulatory approval.”
The MAA for the Flutiform formoterol/fluticasone DPI was delayed when the Concerned Member States failed to reach consensus on the application. In the US, the FDA issued a complete response letter regarding the Flutiform NDA in January 2010.
SkyePharma Chairman Frank Condella commented, “We would like to thank Axel for all his efforts on behalf of the Group and wish him well in his future endeavours. We are pleased that we have an appropriate replacement in Peter Grant. Peter’s knowledge of the Group, understanding of the finances, excellent track record in reducing SkyePharma’s cost base and experience of the Flutiform development and regulatory process over the past five years make him the ideal candidate to take the Company forward. Peter will continue to have responsibility for the Group’s finances in his new role, supported by a strong financial team.”
Read the SkyePharma press release.
